查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1598389

治療性疫苗市場：按疫苗類型、適應症、給藥方法、最終用戶分類 - 2025-2030 年全球預測

Therapeutic Vaccines Market by Vaccines Type (Auto-Immune Diseases Vaccines, Chronic Disease Vaccines, Infectious Diseases Vaccines), Disease Indication (Dengue, DTP, Hepatitis), Administration, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年治療性疫苗市場估值為300.8億美元，預計到2024年將達到330.5億美元，複合年成長率為10.35%，到2030年將達到599.5億美元。

治療性疫苗是醫療保健產業的一個變革部分，與傳統疫苗不同，治療性疫苗旨在治療現有疾病，而不是預防疾病。它的工作原理是利用人體的免疫反應來瞄準並消除特定的病原體或癌細胞。治療性疫苗的需求源於對癌症、自體免疫疾病和感染疾病等慢性和危及生命的疾病進行更有效和更有針對性的治療的需要。這些疫苗可應用於癌症、感染疾病和各種慢性疾病，最終用戶包括醫療保健提供者、研究機構和製藥公司。由於生物技術的進步、研發投資的增加以及全球慢性病發病率的上升，預計治療性疫苗市場將大幅成長。個人化醫療、生物製藥的擴散以及人工智慧和機器學習在疫苗開發中的整合等因素正在為創新和進步創造肥沃的土壤。該市場的新機會包括探索新的疫苗配方、聯合治療以及擴大對其他挑戰性疾病的適用性。然而，高昂的開發成本、嚴格的監管障礙以及高定價導致的市場滲透率有限等挑戰正在影響市場成長。此外，製造複雜性和安全性問題是臨床試驗的主要瓶頸。為了促進創新和業務成長，應重點關注次世代定序、生物標記發現和新佐劑技術的開發。重要的是要注重合作夥伴關係關係，以加速研究和開發、簡化監管流程以及增加政府和非政府組織的資金籌措。整體而言，市場發展迅速，競爭格局激烈。能夠有效應對現有挑戰並適應技術變革的公司將擁有明顯的優勢和巨大的成長潛力。

主要市場統計
基準年[2023] 300.8億美元
預測年份 [2024] 330.5億美元
預測年份 [2030] 599.5億美元
複合年成長率（%） 10.35%

市場動態：快速發展的治療性疫苗市場的關鍵市場洞察

供需的動態交互作用正在改變治療性疫苗市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 慢性病、感染疾病等疾病盛行率上升
    • 對標靶疾病的生技藥品和藥物的需求不斷增加
    • 政府增加疫苗研發資金
  • 市場限制因素
    • 與治療性疫苗相關的副作用
    • 關於疫苗核准的嚴格政府法規
  • 市場機會
    • 政府和私人組織擴大舉措來促進疫苗接種
    • 介紹基於胜肽的治療性疫苗和肺炎球菌疫苗等新疫苗
    • 活性化研發活動和正在進行中的疫苗開發
  • 市場挑戰
    • 疫苗生產臨床試驗的延誤
    • 開發治療性疫苗的高成本

波特的五力戰略工具駕馭治療性疫苗市場

波特的五力框架是了解治療性疫苗市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解治療性疫苗市場的外部影響

外部宏觀環境因素在塑造治療性疫苗市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解治療性疫苗市場的競爭狀況

對治療性疫苗市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣治療疫苗市場供應商的績效評估

FPNV定位矩陣是評估治療性疫苗市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了治療性疫苗市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對治療性疫苗市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病、感染疾病等疾病發生率增加
      • 針對目標疾病的生技藥品和藥物的需求增加
      • 政府增加疫苗研發資金
    • 抑制因素
      • 與治療性疫苗相關的副作用
      • 政府對疫苗核准有嚴格規定
    • 機會
      • 政府和私人組織正在加強促進疫苗接種。
      • 介紹基於胜肽的治療性疫苗和肺炎球菌疫苗等新疫苗
      • 增加研發活動和正在進行的疫苗開發
    • 任務
      • 一些疫苗生產的臨床試驗進展緩慢
      • 開發治療性疫苗的高成本
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 依疫苗類型分類的治療性疫苗市場

  • 自體免疫疾病疫苗
  • 慢性病疫苗
  • 感染疾病疫苗
  • 神經系統疾病疫苗

第7章 治療性疫苗市場：依疾病適應症

  • 登革熱
  • DTP
  • 肝炎
  • 人類乳突病毒
  • 流感
  • 病菌感染感染
  • MMR
  • 肺炎鏈球菌感染
  • 脊髓灰質炎
  • 水痘

第8章治療性疫苗市場的管理

  • 肌肉內和皮下給藥
  • 口服給藥

第9章 治療性疫苗市場：依最終使用者分類

  • 成人
  • 小兒科

第10章美洲治療性疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太治療疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的治療性疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AFFiRiS AG
  • Agenus Inc.
  • Argos Therapeutics Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Celldex Therapeutics, Inc.
  • CSL Limited
  • Emergent Biosolutions, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
Product Code: MRR-030298DFF753

The Therapeutic Vaccines Market was valued at USD 30.08 billion in 2023, expected to reach USD 33.05 billion in 2024, and is projected to grow at a CAGR of 10.35%, to USD 59.95 billion by 2030.

Therapeutic vaccines represent a transformative segment in the healthcare industry, designed to treat existing diseases rather than prevent them, unlike traditional vaccines. They function by harnessing the body's immune response to target and eliminate specific pathogens or cancerous cells. The necessity for therapeutic vaccines arises from the need for more effective and targeted treatments for chronic and life-threatening diseases such as cancer, autoimmune disorders, and infectious diseases where traditional therapeutic approaches prove inadequate or detrimental. These vaccines find applications across oncology, infectious diseases, and various chronic conditions, with end-users spanning healthcare providers, research organizations, and pharmaceutical companies. The market for therapeutic vaccines is poised for significant growth, driven by advancements in biotechnology, increasing research and development investments, and rising incidences of chronic diseases globally. Factors such as personalized medicine, the proliferation of biopharmaceuticals, and the integration of AI and machine learning in vaccine development create a fertile ground for innovation and progress. Emerging opportunities in the market include exploring new vaccine formulations, combination therapies, and expanding the application scope to other challenging diseases. However, challenges such as high developmental costs, stringent regulatory hurdles, and limited market penetration due to high pricing affect market growth. Additionally, manufacturing complexities and safety concerns in clinical trials pose significant bottlenecks. To foster innovation and business growth, focus should be directed towards next-generation sequencing, biomarker discovery, and the development of new adjuvant technologies. A strong emphasis on collaborative partnerships for accelerated R&D, streamlined regulatory processes, and increased funding from governmental and non-governmental entities will be critical. Overall, the market is characterized by rapid advancements and a competitive landscape. Companies that can adapt to technological changes while effectively navigating the existing challenges will have a distinctive edge and significant growth potential.

KEY MARKET STATISTICS
Base Year [2023] USD 30.08 billion
Estimated Year [2024] USD 33.05 billion
Forecast Year [2030] USD 59.95 billion
CAGR (%) 10.35%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Therapeutic Vaccines Market

The Therapeutic Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence rate of diseases such as chronic and infectious diseases
    • Rising demand for biologics and drugs for targeted diseases
    • Growing government funding for vaccine development
  • Market Restraints
    • Side effects associated with therapeutic vaccines
    • Stringent government regulations for the approval of vaccines
  • Market Opportunities
    • Growing initiatives from government and private organizations to advance vaccination
    • Introduction of novel vaccines such as peptide-based therapeutic vaccines, and pneumococcal vaccines
    • Rising R&D activities and vaccines developments in the pipeline
  • Market Challenges
    • Slow processing of clinical trials for the production of some vaccine
    • High cost associated with the development of the therapeutic vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Therapeutic Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Therapeutic Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Therapeutic Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Therapeutic Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Therapeutic Vaccines Market

A detailed market share analysis in the Therapeutic Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Therapeutic Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Therapeutic Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Therapeutic Vaccines Market

A strategic analysis of the Therapeutic Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Therapeutic Vaccines Market, highlighting leading vendors and their innovative profiles. These include AFFiRiS AG, Agenus Inc., Argos Therapeutics Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bavarian Nordic A/S, Celldex Therapeutics, Inc., CSL Limited, Emergent Biosolutions, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., and Serum Institute of India Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Therapeutic Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Vaccines Type, market is studied across Auto-Immune Diseases Vaccines, Chronic Disease Vaccines, Infectious Diseases Vaccines, and Neurological Disease Vaccines.
  • Based on Disease Indication, market is studied across Dengue, DTP, Hepatitis, Human Papilloma Virus, Influenza, Meningococcal Disease, MMR, Pneumococcal Disease, Polio, and Varicella.
  • Based on Administration, market is studied across Intramuscular & Subcutaneous Administration and Oral Administration.
  • Based on End-User, market is studied across Adults and Pediatrics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence rate of diseases such as chronic and infectious diseases
      • 5.1.1.2. Rising demand for biologics and drugs for targeted diseases
      • 5.1.1.3. Growing government funding for vaccine development
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with therapeutic vaccines
      • 5.1.2.2. Stringent government regulations for the approval of vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing initiatives from government and private organizations to advance vaccination
      • 5.1.3.2. Introduction of novel vaccines such as peptide-based therapeutic vaccines, and pneumococcal vaccines
      • 5.1.3.3. Rising R&D activities and vaccines developments in the pipeline
    • 5.1.4. Challenges
      • 5.1.4.1. Slow processing of clinical trials for the production of some vaccine
      • 5.1.4.2. High cost associated with the development of the therapeutic vaccines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Therapeutic Vaccines Market, by Vaccines Type

  • 6.1. Introduction
  • 6.2. Auto-Immune Diseases Vaccines
  • 6.3. Chronic Disease Vaccines
  • 6.4. Infectious Diseases Vaccines
  • 6.5. Neurological Disease Vaccines

7. Therapeutic Vaccines Market, by Disease Indication

  • 7.1. Introduction
  • 7.2. Dengue
  • 7.3. DTP
  • 7.4. Hepatitis
  • 7.5. Human Papilloma Virus
  • 7.6. Influenza
  • 7.7. Meningococcal Disease
  • 7.8. MMR
  • 7.9. Pneumococcal Disease
  • 7.10. Polio
  • 7.11. Varicella

8. Therapeutic Vaccines Market, by Administration

  • 8.1. Introduction
  • 8.2. Intramuscular & Subcutaneous Administration
  • 8.3. Oral Administration

9. Therapeutic Vaccines Market, by End-User

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Pediatrics

10. Americas Therapeutic Vaccines Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Therapeutic Vaccines Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Therapeutic Vaccines Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AFFiRiS AG
  • 2. Agenus Inc.
  • 3. Argos Therapeutics Inc.
  • 4. Astellas Pharma, Inc.
  • 5. AstraZeneca PLC
  • 6. Bavarian Nordic A/S
  • 7. Celldex Therapeutics, Inc.
  • 8. CSL Limited
  • 9. Emergent Biosolutions, Inc.
  • 10. GlaxoSmithKline PLC
  • 11. Johnson & Johnson Services, Inc.
  • 12. Merck & Co., Inc.
  • 13. Pfizer, Inc.
  • 14. Sanofi S.A.
  • 15. Serum Institute of India Pvt. Ltd.

LIST OF FIGURES

  • FIGURE 1. THERAPEUTIC VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. THERAPEUTIC VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. THERAPEUTIC VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. THERAPEUTIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THERAPEUTIC VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THERAPEUTIC VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY AUTO-IMMUNE DISEASES VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY CHRONIC DISEASE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFECTIOUS DISEASES VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY NEUROLOGICAL DISEASE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DENGUE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY DTP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY HUMAN PAPILLOMA VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MENINGOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY MMR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES THERAPEUTIC VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY VACCINES TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM THERAPEUTIC VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. THERAPEUTIC VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 198. THERAPEUTIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2023